Literature DB >> 8320245

Results with retrograde delivery of cardioplegia for myocardial protection during cardiac surgery.

R W Emery1, K V Arom.   

Abstract

From November 19, 1990 through November 18, 1991 242 consecutive patients underwent cardioplegic arrest using retrograde delivery of crystalloid cardioplegia via blind transatrial cannulation of the coronary sinus. Of these procedures 196 (81%) were coronary artery bypass procedures. The overall operative mortality was 0.4%. Ten patients (3%) had enzyme and/or ECG criteria for myocardial damage in the peri-operative period and there was one deep sternal wound infection (0.4%). Two patients required VAD assistance post-operative, one following Protamine reaction (LVAD) and one following RV infarction and failed PTCA (RVAD). Both survived. Ninety-seven patients (40%) developed supraventricular arrhythmias and 20% required temporary pacing post-op for less than 6 hours. These results indicate the safety and effectiveness of retrograde delivery of intermittent crystalloid cardioplegia solution in general cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320245

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  2 in total

1.  Comparison of antegrade with antegrade/retrograde cold blood cardioplegia for myocardial revascularization.

Authors:  A C Cernaianu; D R Flum; M Maurer; J H Cilley; M A Grosso; L Browstein; A J DelRossi
Journal:  Tex Heart Inst J       Date:  1996

2.  A retrospective analysis of myocardial preservation techniques during coronary artery bypass graft surgery: are we protecting the heart?

Authors:  Luciano Candilio; Abdul Malik; Con Ariti; Sherbano A Khan; Matthew Barnard; Carmelo Di Salvo; David R Lawrence; Martin P Hayward; John A Yap; Amir M Sheikh; Christopher G A McGregor; Shyam K Kolvekar; Derek J Hausenloy; Derek M Yellon; Neil Roberts
Journal:  J Cardiothorac Surg       Date:  2014-12-31       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.